Detailed information for compound 458191

Basic information

Technical information
  • TDR Targets ID: 458191
  • Name: 3-[3,5-dibromo-4-[(3-bromophenyl)methoxy]phen yl]propanoic acid
  • MW: 492.985 | Formula: C16H13Br3O3
  • H donors: 1 H acceptors: 2 LogP: 5.22 Rotable bonds: 6
    Rule of 5 violations (Lipinski): 1
  • SMILES: OC(=O)CCc1cc(Br)c(c(c1)Br)OCc1cccc(c1)Br
  • InChi: 1S/C16H13Br3O3/c17-12-3-1-2-11(6-12)9-22-16-13(18)7-10(8-14(16)19)4-5-15(20)21/h1-3,6-8H,4-5,9H2,(H,20,21)
  • InChiKey: LKIKBJBECFALSP-UHFFFAOYSA-N  

Network

Hover on a compound node to display the structore

Synonyms

  • 3-[3,5-dibromo-4-(3-bromobenzyl)oxy-phenyl]propionic acid

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens progesterone receptor Starlite/ChEMBL References
Homo sapiens nuclear receptor subfamily 3, group C, member 2 Starlite/ChEMBL References
Homo sapiens nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) Starlite/ChEMBL References
Homo sapiens androgen receptor Starlite/ChEMBL References
Homo sapiens thyroid hormone receptor, alpha Starlite/ChEMBL References
Homo sapiens thyroid hormone receptor, beta Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
Species Potential target Known druggable target/s Ortholog Group
Echinococcus granulosus Mitotic checkpoint protein PRCC C terminal Get druggable targets OG5_134830 All targets in OG5_134830
Schistosoma japonicum ko:K08362 nuclear receptor, subfamily 1, group A, member 2, putative Get druggable targets OG5_134830 All targets in OG5_134830
Echinococcus multilocularis Mitotic checkpoint protein PRCC, C terminal Get druggable targets OG5_134830 All targets in OG5_134830
Schistosoma japonicum Thyroid hormone receptor alpha, putative Get druggable targets OG5_134830 All targets in OG5_134830
Brugia malayi Nuclear hormone receptor-like 1 Get druggable targets OG5_156853 All targets in OG5_156853
Brugia malayi Nuclear hormone receptor-like 1 Get druggable targets OG5_156853 All targets in OG5_156853
Brugia malayi Nuclear hormone receptor-like 1 Get druggable targets OG5_156853 All targets in OG5_156853
Schistosoma mansoni hypothetical protein Get druggable targets OG5_134830 All targets in OG5_134830
Loa Loa (eye worm) hypothetical protein Get druggable targets OG5_156853 All targets in OG5_156853
Schistosoma mansoni thyroid hormone receptor Get druggable targets OG5_134830 All targets in OG5_134830
Schistosoma mansoni thyroid hormone receptor Get druggable targets OG5_134830 All targets in OG5_134830
Schistosoma japonicum Thyroid hormone receptor alpha, putative Get druggable targets OG5_134830 All targets in OG5_134830
Schistosoma japonicum expressed protein Get druggable targets OG5_134830 All targets in OG5_134830
Loa Loa (eye worm) nuclear hormone receptor-like 1 Get druggable targets OG5_156853 All targets in OG5_156853
Echinococcus multilocularis thyroid hormone receptor alpha Get druggable targets OG5_134830 All targets in OG5_134830

By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Brugia malayi photoreceptor-specific nuclear receptor thyroid hormone receptor, alpha 451 aa 372 aa 25.3 %
Brugia malayi photoreceptor-specific nuclear receptor thyroid hormone receptor, beta 461 aa 414 aa 24.6 %

Obtained from network model

Ranking Plot


Putative Targets List


Species Potential target Raw Global Species
Schistosoma mansoni thyroid hormone receptor 0.0216 0 0.5
Loa Loa (eye worm) nuclear hormone receptor-like 1 0.0322 0.7776 1
Echinococcus multilocularis thyroid hormone receptor alpha 0.0216 0 0.5
Schistosoma mansoni thyroid hormone receptor 0.0216 0 0.5

Activities

Activity type Activity value Assay description Source Reference
Activity (functional) = 63 % Antagonist activity at human TRbeta1 expressed in CHO cells assessed as TRAFbeta1-driven gene transactivation by alkaline phosphatase reporter gene assay ChEMBL. 17254783
Activity (functional) = 63 % Antagonist activity at human TRbeta1 expressed in CHO cells assessed as TRAFbeta1-driven gene transactivation by alkaline phosphatase reporter gene assay ChEMBL. 17254783
Activity (functional) = 80 % Antagonist activity at human TRalpha1 expressed in CHO cells assessed as TRAFalpha1-driven gene transactivation by alkaline phosphatase reporter gene assay ChEMBL. 17254783
Activity (functional) = 80 % Antagonist activity at human TRalpha1 expressed in CHO cells assessed as TRAFalpha1-driven gene transactivation by alkaline phosphatase reporter gene assay ChEMBL. 17254783
IC50 (binding) = 60 nM Binding affinity at human TRbeta1 ChEMBL. 17254783
IC50 (binding) = 60 nM Binding affinity at human TRbeta1 ChEMBL. 17254783
IC50 (binding) = 90 nM Displacement of L-T3 from human TRalpha1 expressed in CHOK1 cells assessed as TRAFalpha1-driven gene transactivation by alkaline phosphatase reporter gene assay ChEMBL. 17254783
IC50 (binding) = 90 nM Displacement of L-T3 from human TRalpha1 expressed in CHOK1 cells assessed as TRAFalpha1-driven gene transactivation by alkaline phosphatase reporter gene assay ChEMBL. 17254783
IC50 (binding) = 99 nM Binding affinity at human TRalpha1 ChEMBL. 17254783
IC50 (binding) = 99 nM Binding affinity at human TRalpha1 ChEMBL. 17254783
IC50 (functional) = 230 nM Antagonist activity at human TRbeta1 expressed in CHO cells assessed as TRAFbeta1-driven gene transactivation by alkaline phosphatase reporter gene assay ChEMBL. 17254783
IC50 (functional) = 230 nM Antagonist activity at human TRbeta1 expressed in CHO cells assessed as TRAFbeta1-driven gene transactivation by alkaline phosphatase reporter gene assay ChEMBL. 17254783
IC50 (functional) = 380 nM Antagonist activity at human TRalpha1 expressed in CHO cells assessed as TRAFalpha1-driven gene transactivation by alkaline phosphatase reporter gene assay ChEMBL. 17254783
IC50 (functional) = 380 nM Antagonist activity at human TRalpha1 expressed in CHO cells assessed as TRAFalpha1-driven gene transactivation by alkaline phosphatase reporter gene assay ChEMBL. 17254783
IC50 (binding) = 2500 nM Binding affinity at PR ChEMBL. 17254783
IC50 (binding) = 2500 nM Binding affinity at PR ChEMBL. 17254783
IC50 (binding) = 7700 nM Binding affinity at AR ChEMBL. 17254783
IC50 (binding) = 7700 nM Binding affinity at AR ChEMBL. 17254783
IC50 (binding) = 8700 nM Binding affinity at MR ChEMBL. 17254783
IC50 (binding) = 8700 nM Binding affinity at MR ChEMBL. 17254783
IC50 (binding) = 14000 nM Binding affinity at GR ChEMBL. 17254783
IC50 (binding) = 14000 nM Binding affinity at GR ChEMBL. 17254783
IC50 (binding) = 29000 nM Binding affinity at ERalpha ChEMBL. 17254783
IC50 (binding) = 29000 nM Binding affinity at ERalpha ChEMBL. 17254783
Ratio IC50 (binding) = 0.97 Selectivity for human TRalpha1 to human TRbeta1 ChEMBL. 17254783
Selectivity ratio (binding) = 25 Selectivity for human TRalpha1 over PR ChEMBL. 17254783
Selectivity ratio (binding) > 100 Selectivity for human TRalpha1 over AR ChEMBL. 17254783
Selectivity ratio (binding) > 100 Selectivity for human TRalpha1 over ERalpha ChEMBL. 17254783
Selectivity ratio (binding) > 100 Selectivity for human TRalpha1 over GR ChEMBL. 17254783
Selectivity ratio (binding) > 100 Selectivity for human TRalpha1 over MR ChEMBL. 17254783

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.